🚚 Free shipping on all orders above $299 · 30 days money back guarantee · Helpline +1 251-332-4105

Nirmatrelvir 150 And Ritonavir 100

$120.00$4.00 per tablet · 30 tablets
Choose pack sizePrice per tablet shown

Want to order in bulk / B2B price?

Tracked, discreet delivery

Ships in plain packaging with a tracking number. Delivery time for this product: 6 to 15 days. Free shipping on orders above $299.

30 days money back guarantee

Damaged, missing or only part of your order arrived? Choose a new package or a full refund.

Questions before you order?

Call +1 251-332-4105 or email [email protected].

SECURE CHECKOUT
DISCOVER
MasterCard
VISA

Share

Nirmatrelvir 150 mg and ritonavir 100 mg are the strengths of the individual tablets used in the combination treatment. They do not necessarily represent the complete dose taken at one time. The correct number of tablets depends on kidney function and the prescribed regimen.

What Is Nirmatrelvir 150 mg and Ritonavir 100 mg?

Nirmatrelvir 150 mg and Ritonavir 100 mg is an oral antiviral combination used for the early treatment of mild-to-moderate COVID-19 in patients who are at high risk of progressing to severe disease.

The combination contains two active ingredients:

Nirmatrelvir: An antiviral medicine that inhibits the SARS-CoV-2 main protease, an enzyme required for viral replication.

Ritonavir: A pharmacokinetic enhancer that slows the metabolism of nirmatrelvir, helping maintain effective concentrations in the body.

The combination is commonly associated with the reference brand Paxlovid.

COVID-19 is caused by the SARS-CoV-2 virus and can produce symptoms such as fever, cough, sore throat, fatigue, and respiratory discomfort.

Most individuals recover without antiviral therapy. However, certain patients have an increased risk of hospitalization or severe complications.

When prescribed early to eligible patients, nirmatrelvir and ritonavir can reduce the risk of progression to severe COVID-19.

Treatment is most effective when started promptly and must begin within the recommended treatment window.

Important: This medicine is not intended for routine self-treatment, COVID-19 prevention, or treatment of unrelated viral infections. A healthcare professional must review kidney function and potential drug interactions before prescribing it.

How Does Nirmatrelvir and Ritonavir Work?

1. Inhibits the SARS-CoV-2 Main Protease

Nirmatrelvir inhibits the SARS-CoV-2 main protease, also known as Mpro or 3CLpro.

This enzyme is necessary for processing viral polyproteins.

2. Prevents Viral Protein Processing

By blocking the main protease, nirmatrelvir interferes with the production of functional viral proteins.

3. Reduces Viral Replication

Disruption of viral protein processing prevents efficient formation of new viral particles.

4. Ritonavir Boosts Nirmatrelvir Exposure

Ritonavir strongly inhibits CYP3A-mediated metabolism.

This reduces the breakdown of nirmatrelvir and increases its systemic exposure.

5. Maintains Antiviral Concentrations

The combination helps maintain nirmatrelvir concentrations required for antiviral activity.

6. Targets Early Viral Replication

The treatment is intended for early COVID-19, when antiviral therapy can help reduce the risk of progression.

7. Supports Combination Antiviral Treatment

Nirmatrelvir provides the principal antiviral activity against SARS-CoV-2, while ritonavir acts mainly as a pharmacokinetic booster.

Uses of Nirmatrelvir 150 mg and Ritonavir 100 mg

1. Mild-to-Moderate COVID-19 Treatment

The combination is used to treat eligible patients with mild-to-moderate COVID-19 who are at increased risk of severe disease.

2. High-Risk COVID-19 Patients

Treatment may be appropriate for individuals with certain medical conditions or other risk factors for severe COVID-19.

3. Early Antiviral Intervention

Treatment should begin as soon as possible after diagnosis and within five days of symptom onset.

4. Reduction of Hospitalization Risk

Clinical studies have demonstrated a reduction in hospitalization or death among selected high-risk patients treated early.

5. Outpatient COVID-19 Management

The combination can be administered orally outside the hospital in eligible patients.

6. Patients With Risk Factors for Severe Disease

A healthcare professional may consider treatment for patients with risk factors such as advanced age, immunocompromising conditions, or certain chronic diseases.

7. COVID-19 Treatment in Eligible Adults

The combination is approved in the United States for adults with mild-to-moderate COVID-19 who are at high risk of progression.

8. COVID-19 Treatment in Certain Adolescents

Under applicable U.S. emergency-use authorization, treatment may be available for eligible pediatric patients aged 12 years and older who weigh at least 40 kg.

Pediatric authorization and availability vary by country.

Important: This medicine is not used for routine prevention of COVID-19 and should not replace vaccination or other appropriate preventive measures.

How to Take Nirmatrelvir 150 mg and Ritonavir 100 mg

The combination must be taken exactly as prescribed.

General Administration Instructions

  1. Confirm the prescribed treatment regimen.
  2. Begin treatment within five days of COVID-19 symptom onset.
  3. Take nirmatrelvir and ritonavir together as directed.
  4. Swallow the tablets whole with water.
  5. Do not crush, chew, or break the tablets.
  6. The medicine may generally be taken with or without food.
  7. Complete the prescribed five-day treatment course.
  8. Do not exceed the prescribed dose.
  9. Inform the prescriber about all medications and supplements.
  10. Seek medical attention if symptoms worsen.

The standard regimen for eligible adults with normal kidney function or mild renal impairment is:

Nirmatrelvir 300 mg plus ritonavir 100 mg, taken together twice daily for five days.

This means each standard dose contains:

  • Two nirmatrelvir 150 mg tablets
  • One ritonavir 100 mg tablet
Dosage InformationGeneral Reference
Nirmatrelvir Tablet Strength150 mg
Ritonavir Tablet Strength100 mg
Standard Nirmatrelvir Dose300 mg
Standard Ritonavir Dose100 mg
Standard Tablets Per Dose3 tablets
Administration FrequencyTwice daily
Treatment Duration5 days
Standard Total Tablets30 tablets
Treatment InitiationWithin 5 days of symptom onset

Dosage Adjustments for Kidney Function

Kidney function is important when selecting the correct dose.

Kidney FunctionGeneral U.S. Dosing Reference
eGFR 60 mL/min or higherNirmatrelvir 300 mg + ritonavir 100 mg twice daily
eGFR 30 to less than 60 mL/minNirmatrelvir 150 mg + ritonavir 100 mg twice daily
eGFR less than 30 mL/min, including hemodialysisSpecialized reduced regimen with once-daily dosing after an initial loading dose

For severe renal impairment, current U.S. prescribing information includes a specialized regimen: nirmatrelvir 300 mg plus ritonavir 100 mg on day 1, followed by nirmatrelvir 150 mg plus ritonavir 100 mg once daily on days 2–5. On hemodialysis days, the dose is taken after dialysis.

Important: Renal dose adjustment must be determined by the prescriber. Patients should never change the number of tablets based only on the information in this listing.

Can It Be Taken With Food?

Nirmatrelvir and ritonavir may generally be taken with or without food.

What If a Dose Is Missed?

If a dose is missed within eight hours of the usual dosing time, take it as soon as remembered.

If more than eight hours have passed, skip the missed dose and continue with the regular schedule.

Do not double doses.

Can Treatment Continue Beyond Five Days?

The standard treatment duration is five days.

Do not extend or repeat treatment without specific medical guidance.

How Long Does Nirmatrelvir and Ritonavir Take to Work?

The combination begins acting against viral replication after administration.

However, improvement in symptoms may not occur immediately.

The treatment is intended to reduce the risk of disease progression rather than provide instant relief from fever, cough, or fatigue.

Clinical response depends on the patient’s medical history, immune status, symptom severity, and timing of treatment.

Some patients may experience a return of symptoms or positive viral tests after initial improvement, sometimes described as COVID-19 rebound.

Common Side Effects

Possible side effects include:

  • Altered or bitter taste
  • Diarrhea
  • Headache
  • Nausea
  • Vomiting
  • Abdominal discomfort
  • General discomfort

Not every patient experiences these effects.

Potentially Harmful Effects & Serious Health Risks

1. Serious Drug Interactions

Ritonavir strongly inhibits CYP3A and can substantially increase concentrations of certain medicines.

Some interactions may cause life-threatening adverse effects.

2. Severe Allergic Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been reported.

3. Severe Skin Reactions

Serious skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported.

4. Liver Injury

Ritonavir may cause elevated liver enzymes, hepatitis, or other liver-related adverse effects.

Patients with impaired kidney function may experience increased nirmatrelvir exposure if the dose is not appropriately adjusted.

6. Cardiac Rhythm Risks From Drug Interactions

Interactions with certain antiarrhythmic medicines may cause serious cardiac rhythm disturbances.

7. Severe Muscle Toxicity From Interactions

Co-administration with certain statins, particularly simvastatin or lovastatin, can increase the risk of serious muscle injury, including rhabdomyolysis.

8. Excessive Sedation From Interactions

Some sedatives and other central nervous system medicines may accumulate when combined with ritonavir.

9. Reduced Effectiveness From Enzyme Inducers

Strong CYP3A-inducing medicines may reduce nirmatrelvir and ritonavir concentrations, potentially compromising antiviral effectiveness.

10. HIV Drug Resistance Concerns

Ritonavir exposure may contribute to HIV protease inhibitor resistance in patients with uncontrolled or undiagnosed HIV infection.

11. COVID-19 Rebound

Symptoms or positive tests may return after initial improvement.

Rebound does not automatically mean treatment failure, but worsening symptoms require medical evaluation.

12. Disease Progression Despite Treatment

The combination does not guarantee prevention of hospitalization or severe COVID-19.

Patients should seek urgent care for severe breathing difficulty, persistent chest pain, confusion, or other emergency warning signs.

Contraindications & Safety Precautions

1. Serious Drug Interaction Screening

A complete medication review is essential before treatment.

2. CYP3A-Metabolized Medicines

Certain medicines that depend heavily on CYP3A metabolism may be contraindicated because their concentrations can increase dangerously.

3. Strong CYP3A Inducers

Medicines such as rifampin and certain anticonvulsants can reduce antiviral concentrations and may be contraindicated.

4. Statin Interactions

Simvastatin and lovastatin are contraindicated during co-administration. Other statins may require temporary interruption or adjustment.

5. Antiarrhythmic Medicines

Some antiarrhythmic medicines have serious interaction risks.

6. Anticoagulants

Certain anticoagulants may require adjustment, alternative treatment, or close monitoring.

7. Immunosuppressants

Medicines such as tacrolimus and cyclosporine may interact significantly with ritonavir.

Specialist supervision may be necessary.

8. Kidney Disease

Renal function should be assessed before selecting the dose.

9. Liver Disease

The combination is not recommended in severe hepatic impairment under U.S. prescribing information.

10. Previous Hypersensitivity

Patients with a history of clinically significant hypersensitivity to nirmatrelvir, ritonavir, or product components should not use the combination.

11. Pregnancy

Available pregnancy information should be reviewed with the prescriber.

Treatment decisions should consider the risks of untreated COVID-19 and the available clinical evidence.

12. Breastfeeding

Breastfeeding decisions require individualized assessment of treatment benefits, infant exposure, and the risks associated with maternal COVID-19.

13. Hormonal Contraceptives

Ritonavir may affect hormonal contraceptive exposure.

Patients using ethinyl estradiol-containing contraceptives should follow current prescribing guidance regarding additional or alternative contraception.

14. HIV Infection

Patients with HIV should inform their healthcare professional about their diagnosis and antiretroviral regimen.

15. Pediatric Patients

Use in adolescents depends on age, weight, and applicable regulatory authorization.

16. Treatment Timing

Treatment should begin within five days of COVID-19 symptom onset.

17. COVID-19 Vaccination

Nirmatrelvir and ritonavir do not replace vaccination.

18. Medical Monitoring

Healthcare professionals may monitor:

  • Kidney function
  • Liver function when indicated
  • Medication interactions
  • COVID-19 symptom progression
  • Respiratory symptoms
  • Oxygen saturation when indicated
  • Allergic reactions
  • Treatment adherence
  • Gastrointestinal adverse effects
  • Clinical response
  • Symptoms of COVID-19 rebound
  • Need for additional medical care

Advantages

  • Oral combination antiviral treatment.
  • Direct inhibition of the SARS-CoV-2 main protease.
  • Ritonavir-enhanced antiviral exposure.
  • Five-day treatment course.
  • Used for eligible high-risk COVID-19 patients.
  • Can reduce hospitalization risk in appropriate patients.
  • Suitable for outpatient administration.
  • May be taken with or without food.
  • Established standard dosing regimen.
  • Renal-adjusted regimens available.
  • Can be used in selected eligible adults and adolescents according to local authorization.
  • Recommended as a preferred outpatient antiviral option in many clinical guidelines when appropriate.

Disadvantages / Limitations

  • Numerous clinically significant drug interactions.
  • Requires complete medication review.
  • Requires renal dose assessment.
  • May cause altered taste.
  • May cause diarrhea.
  • May cause nausea.
  • May cause headache.
  • May cause vomiting.
  • May cause serious allergic reactions.
  • May cause severe skin reactions.
  • Potential liver-related adverse effects.
  • Some statins are contraindicated during treatment.
  • Some antiarrhythmics are contraindicated.
  • Some anticonvulsants and other enzyme inducers are contraindicated.
  • May interact with anticoagulants.
  • May interact with immunosuppressants.
  • Not recommended in severe hepatic impairment.
  • Must be started early.
  • Does not prevent COVID-19 infection.
  • Does not replace vaccination.
  • Does not guarantee prevention of severe disease.
  • Requires medical supervision.

Important Notes

Generic Name: Nirmatrelvir + Ritonavir.

Strength: Nirmatrelvir 150 mg and Ritonavir 100 mg per respective tablet.

Drug Class: Antiviral Protease Inhibitor Combination.

Therapeutic Category: COVID-19 Antiviral Medicine.

Primary Use: Early treatment of mild-to-moderate COVID-19 in eligible high-risk patients.

Mechanism: SARS-CoV-2 main protease inhibition with ritonavir-mediated pharmacokinetic boosting.

Standard Adult Dose: Nirmatrelvir 300 mg + ritonavir 100 mg twice daily.

Treatment Duration: Five days.

Treatment Window: Within five days of symptom onset.

Administration Route: Oral.

Major Warning: Serious and potentially life-threatening drug interactions.

Renal Warning: Dose adjustment required in moderate or severe renal impairment.

Hepatic Warning: Not recommended in severe hepatic impairment.

Prescription Status: Prescription-Only Medicine.

Monitoring: Kidney function, medication interactions, adverse effects, and clinical response.

Storage: Follow manufacturer instructions.

Frequently Asked Questions

1. What is Nirmatrelvir 150 mg and Ritonavir 100 mg used for?

It is used for early treatment of mild-to-moderate COVID-19 in eligible patients who are at high risk of severe disease.

2. What is the reference brand name?

The reference brand is Paxlovid.

3. Is this combination an antiviral medicine?

Yes. It is an oral antiviral combination.

4. How does nirmatrelvir work?

Nirmatrelvir inhibits the SARS-CoV-2 main protease, interfering with viral replication.

5. What is the role of ritonavir?

Ritonavir slows nirmatrelvir metabolism and increases its exposure in the body.

6. What is the standard adult dose?

The standard regimen is nirmatrelvir 300 mg plus ritonavir 100 mg twice daily for five days, subject to kidney function and other clinical factors.

7. How many tablets are taken per standard dose?

The standard dose contains two 150 mg nirmatrelvir tablets and one 100 mg ritonavir tablet.

8. How many tablets are required for the standard five-day course?

The standard regimen requires 30 tablets in total.

9. When should treatment begin?

Treatment should begin as soon as possible and within five days of COVID-19 symptom onset.

10. Can this medicine be taken with food?

Yes. It may generally be taken with or without food.

Product DetailsInformation
Product NameNirmatrelvir 150 mg and Ritonavir 100 mg
Generic NameNirmatrelvir + Ritonavir
Active IngredientsNirmatrelvir and Ritonavir
StrengthNirmatrelvir 150 mg + Ritonavir 100 mg
Dosage FormOral Film-Coated Tablets
Drug ClassAntiviral Combination / SARS-CoV-2 Protease Inhibitor with Pharmacokinetic Booster
Therapeutic CategoryCOVID-19 Antiviral Medicines
Primary UseTreatment of mild-to-moderate COVID-19 in eligible high-risk patients
Treatment TypeOral Combination Antiviral Therapy
Administration RouteOral
Reference BrandPaxlovid
ManufacturerVerify from product packaging
Pack SizeVerify from product packaging
Prescription StatusPrescription-Only Medicine
StorageFollow manufacturer instructions; U.S. labeling specifies 20–25°C, with permitted excursions
Pack sizes30 tablets, 60 tablets, 90 tablets, 150 tablets, 300 tablets, 510 tablets, 1050 tablets

Reviews

There are no reviews yet.

Be the first to review “Nirmatrelvir 150 And Ritonavir 100”

Your email address will not be published. Required fields are marked *

Bulk / B2B price inquiry

Tell us what you need and we’ll reply by email.